In this edition, Krishnangi explores the Aptima HPV Assay, an FDA PMA-approved molecular diagnostic assay designed for primary cervical cancer screening through detection of high-risk HPV E6/E7 messenger RNA. Through her coverage, Krishnangi highlights the assay’s transcription-mediated amplification workflow, its role in improving specificity for clinically significant HPV infections, and its broader potential to advance molecular women’s health diagnostics through risk-based cervical cancer screening strategies.
(Click anywhere on the image to expand)
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org.
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open-source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer-to-peer mentoring and support.
